Thomas Lee
About Thomas Lee
Thomas Barnes is the CEO of Intellia Therapeutics, co-founder of Eleven Biotherapeutics, and an expert in gene editing and biological systems.
Chief Executive Officer
Thomas Barnes serves as the Chief Executive Officer. His leadership positions have been anchored in both scientific innovation and corporate strategy. His role as CEO extends beyond administrative oversight to include strategic planning, operational management, and external representation of the company.
Co-founded Intellia Therapeutics and Eleven Biotherapeutics
Thomas Barnes co-founded Intellia Therapeutics and Eleven Biotherapeutics, contributing significantly to the biotech sector. Intellia Therapeutics is recognized for its work in CRISPR/Cas9 gene editing technologies, while Eleven Biotherapeutics focuses on protein engineering and small molecule drug repositioning.
Chief Scientific Officer at Intellia Therapeutics
As the Chief Scientific Officer at Intellia Therapeutics, Thomas Barnes helped build a robust research team and played a pivotal role in raising funds. Under his scientific leadership, Intellia expanded its research capabilities and successfully conducted an initial public offering (IPO). He also acted as a corporate spokesperson on advancements and trends within the CRISPR landscape.
Educational Background and Research Fellowships
Thomas Barnes earned a PhD from the University of Cambridge, one of the world's leading institutions. Supplementing his academic achievements, he completed research fellowships at Harvard Medical School and McGill University. These experiences equipped him with extensive knowledge of biological systems, gene editing, genomics, gene discovery, and protein engineering.
Executive Partner at MPM Capital
In addition to his other roles, Thomas Barnes is currently an Executive Partner at MPM Capital. This position involves providing strategic guidance and leveraging his scientific expertise to support the firm's investment decisions in the life sciences sector.